Physician profile
Michael G Cope
NPI 1588639959
$146,891.00
in general payments reported to CMS, 2019-2025
34 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $196 · 2021: $20K · 2022: $38K · 2023: $13K · 2024: $36K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $71K · Food and Beverage: $1,916 · Travel and Lodging: $482 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $71,161.03 |
| Food and Beverage | $1,915.83 |
| Travel and Lodging | $481.76 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $119,497.87 | 2021-2025 | Nexplanon, Jada System |
| Merck Sharp & Dohme LLC | $24,353.68 | 2019-2021 | |
| Astellas Pharma US INC | $388.96 | 2020-2025 | Veozah |
| Abbvie INC. | $368.98 | 2019-2023 | Lo Loestrin Fe, Botox |
| Bayer Healthcare Pharmaceuticals INC. | $311.42 | 2019-2025 | |
| Pfizer INC. | $296.07 | 2021-2025 | |
| Minerva Surgical, INC | $208.45 | 2019-2025 | |
| Therapeuticsmd, INC. | $162.30 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $142.52 | 2025 | Myfembree |
| Mayne Pharma Commercial LLC | $134.31 | 2021-2025 | |
| Biogen, INC. | $115.85 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $108.81 | 2020-2025 | Slynd |
| Intuitive Surgical, INC. | $101.17 | 2019 | |
| Avion Pharmaceuticals | $82.95 | 2019-2022 | |
| Evofem Biosciences, INC. | $79.02 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $65.38 | 2023 | Myrisk |
| Hologic Sales and Service, LLC | $58.27 | 2019-2021 | |
| Gynesonics, INC. | $47.25 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Shield Therapeutics INC | $45.87 | 2024-2025 | |
| Mylan Pharmaceuticals INC. | $41.50 | 2020-2022 | |
| Allergan, INC. | $37.61 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $30.70 | 2019-2020 | |
| Myovant Sciences INC. | $30.00 | 2021-2022 | |
| Lupin INC. | $27.80 | 2020 | |
| Coloplast Corp | $27.41 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.86 | 2020 | |
| Scynexis, INC. | $16.67 | 2022 | |
| Conmed Corporation | $16.51 | 2021 | |
| Agile Therapeutics, INC. | $15.43 | 2021 | |
| Duchesnay USA Incorporated | $15.18 | 2019 | |
| Urovant Sciences INC | $14.59 | 2022 | |
| Pharmacosmos Therapeutics INC. | $13.67 | 2023 | Monoferric |
| Kowa Pharmaceuticals America, INC. | $13.60 | 2023 | Seglentis |
| Kinex Medical Company LLC | $4.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.